News stories about Selecta Biosciences (NASDAQ:SELB) have been trending somewhat positive on Wednesday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Selecta Biosciences earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.4267213027078 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Selecta Biosciences (NASDAQ:SELB) traded up $0.43 during trading on Wednesday, reaching $10.24. 159,300 shares of the company’s stock traded hands, compared to its average volume of 157,650. The company has a debt-to-equity ratio of 0.32, a current ratio of 9.48 and a quick ratio of 9.48. The company has a market capitalization of $219.12, a P/E ratio of -3.30 and a beta of -7.16. Selecta Biosciences has a 1-year low of $8.70 and a 1-year high of $24.02.
A number of research analysts have recently commented on the stock. Canaccord Genuity restated a “buy” rating on shares of Selecta Biosciences in a research report on Wednesday. UBS Group lowered shares of Selecta Biosciences from a “buy” rating to a “neutral” rating in a research report on Thursday, November 9th. Zacks Investment Research raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, October 12th. Finally, ValuEngine downgraded shares of Selecta Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $23.50.
COPYRIGHT VIOLATION WARNING: “Selecta Biosciences (SELB) Earns Media Impact Rating of 0.16” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/03/selecta-biosciences-selb-earns-media-impact-rating-of-0-16.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.